Figure 2
BDNF is sufficient to establish a ZIP-reversible persistent sensitization and is required for initiation and maintenance of persistent sensitization. A) BDNF was injected i.t. causing 3 days of allodynia in mice (left) and myristoylated-ZIP or Scr-ZIP were injected i.t. 8 days following BDNF injection. ZIP treatment blocked PGE2-precipitated persistent sensitization (right). B) IL-6 was injected i.pl. and the BDNF sequestering agent, TrkB/Fc was given i.t. at the same time, dose-dependently blocking IL-6-induced allodynia (left) and PGE2-precipitated persistent sensitization (right). C) A single i.t. treatment with TrkB/Fc 4 days after i.pl. IL-6 injection was sufficient to attenuate PGE2-precipitated persistent sensitization. D) The small molecule TrkB antagonist, ANA-12) given i.p. at the same time as i.pl. Il-6 and again 24 and 48 hrs later blocked IL-6-induced allodynia (left) and PGE2-precipitated persistent sensitization (right). E) Systemic treatment with ANA-12 4 and 5 days after i.pl. IL-6 injection reduced PGE2-precipitated persistent sensitization. All experiments N = 6. * p < 0.05, ** p < 0.01, *** p < 0.001, two way ANOVA with Bonferroni post hoc test.